1. Home
  2. SSYS vs URGN Comparison

SSYS vs URGN Comparison

Compare SSYS & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SSYS
  • URGN
  • Stock Information
  • Founded
  • SSYS 1989
  • URGN 2004
  • Country
  • SSYS United States
  • URGN United States
  • Employees
  • SSYS N/A
  • URGN N/A
  • Industry
  • SSYS Computer peripheral equipment
  • URGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • SSYS Technology
  • URGN Health Care
  • Exchange
  • SSYS Nasdaq
  • URGN Nasdaq
  • Market Cap
  • SSYS 942.7M
  • URGN 904.0M
  • IPO Year
  • SSYS 1994
  • URGN 2017
  • Fundamental
  • Price
  • SSYS $9.69
  • URGN $18.74
  • Analyst Decision
  • SSYS Strong Buy
  • URGN Strong Buy
  • Analyst Count
  • SSYS 3
  • URGN 8
  • Target Price
  • SSYS $14.33
  • URGN $28.50
  • AVG Volume (30 Days)
  • SSYS 1.3M
  • URGN 1.1M
  • Earning Date
  • SSYS 08-13-2025
  • URGN 11-05-2025
  • Dividend Yield
  • SSYS N/A
  • URGN N/A
  • EPS Growth
  • SSYS N/A
  • URGN N/A
  • EPS
  • SSYS N/A
  • URGN N/A
  • Revenue
  • SSYS $564,499,000.00
  • URGN $94,238,000.00
  • Revenue This Year
  • SSYS N/A
  • URGN $35.60
  • Revenue Next Year
  • SSYS $3.06
  • URGN $129.54
  • P/E Ratio
  • SSYS N/A
  • URGN N/A
  • Revenue Growth
  • SSYS N/A
  • URGN 10.85
  • 52 Week Low
  • SSYS $6.28
  • URGN $3.42
  • 52 Week High
  • SSYS $12.88
  • URGN $21.71
  • Technical
  • Relative Strength Index (RSI)
  • SSYS 39.47
  • URGN 48.50
  • Support Level
  • SSYS $9.62
  • URGN $18.45
  • Resistance Level
  • SSYS $10.37
  • URGN $21.71
  • Average True Range (ATR)
  • SSYS 0.41
  • URGN 1.17
  • MACD
  • SSYS -0.08
  • URGN -0.18
  • Stochastic Oscillator
  • SSYS 4.12
  • URGN 17.51

About SSYS Stratasys Ltd. (Israel)

Stratasys Ltd is a polymer-based 3D printing solution, which provides a product life cycle, with multiple technologies and complete solutions for superior application fit, across industrial, healthcare, and consumer fields. It focuses, in particular, on polymer 3D printing solutions that address the fastest-growing manufacturing solutions viewed as the potential growth opportunity in the 3D printing industry. Its printers include FDM, PolyJet, Stereolithography, P3, and SAF. Its software is GrabCAD Software, Connectivity, Digital Anatomy Creator, and OpenAM Software. It generates revenue through 3D printing systems, related services, and consumables and by providing additive manufacturing solutions.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Share on Social Networks: